Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan 21;24(3):2137.
doi: 10.3390/ijms24032137.

Genetic Predisposition to Colorectal Cancer: How Many and Which Genes to Test?

Francesca Rebuzzi  1 , Paola Ulivi  1 , Gianluca Tedaldi  1
Affiliations
Review

Genetic Predisposition to Colorectal Cancer: How Many and Which Genes to Test?

Francesca Rebuzzi et al. Int J Mol Sci. .

Abstract

Colorectal cancer is one of the most common tumors, and genetic predisposition is one of the key risk factors in the development of this malignancy. Lynch syndrome and familial adenomatous polyposis are the best-known genetic diseases associated with hereditary colorectal cancer. However, some other genetic disorders confer an increased risk of colorectal cancer, such as Li-Fraumeni syndrome (TP53 gene), MUTYH-associated polyposis (MUTYH gene), Peutz-Jeghers syndrome (STK11 gene), Cowden syndrome (PTEN gene), and juvenile polyposis syndrome (BMPR1A and SMAD4 genes). Moreover, the recent advances in molecular techniques, in particular Next-Generation Sequencing, have led to the identification of many new genes involved in the predisposition to colorectal cancers, such as RPS20, POLE, POLD1, AXIN2, NTHL1, MSH3, RNF43 and GREM1. In this review, we summarized the past and more recent findings in the field of cancer predisposition genes, with insights into the role of the encoded proteins and into the associated genetic disorders. Furthermore, we discussed the possible clinical utility of genetic testing in terms of prevention protocols and therapeutic approaches.

Keywords: Next-Generation Sequencing; cancer predisposition; cancer risk; gene panels; hereditary colorectal cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Magrin L., Fanale D., Brando C., Fiorino A., Corsini L.R., Sciacchitano R., Filorizzo C., Dimino A., Russo A., Bazan V. POLE, POLD1, and NTHL1: The last but not the least hereditary cancer-predisposing genes. Oncogene. 2021;40:5893–5901. doi: 10.1038/s41388-021-01984-2. - DOI - PubMed
    1. Hampel H., Kalady M.F., Pearlman R., Stanich P.P. Hereditary Colorectal Cancer. Hematol. Oncol. Clin. N. Am. 2022;36:429–447. doi: 10.1016/j.hoc.2022.02.002. - DOI - PubMed
    1. Stadler Z.K., Maio A., Chakravarty D., Kemel Y., Sheehan M., Salo-Mullen E., Tkachuk K., Fong C.J., Nguyen B., Erakky A., et al. Therapeutic Implications of Germline Testing in Patients With Advanced Cancers. J. Clin. Oncol. 2021;39:2698–2709. doi: 10.1200/JCO.20.03661. - DOI - PMC - PubMed
    1. Uson P.L.S., Riegert-Johnson D., Boardman L., Kisiel J., Mountjoy L., Patel N., Lizaola-Mayo B., Borad M.J., Ahn D., Sonbol M.B., et al. Germline Cancer Susceptibility Gene Testing in Unselected Patients With Colorectal Adenocarcinoma: A Multicenter Prospective Study. Clin. Gastroenterol. Hepatol. 2022;20:e508–e528. doi: 10.1016/j.cgh.2021.04.013. - DOI - PubMed

MeSH terms